Bio-Techne Prevails in Second Case Against Miltenyi Biotec for Reverse Engineering of Antibodies Corporation announced today that it has successfully won another legal claim against Miltenyi Biotec B.V. & Co. KG, which allegedly commercialized antibodies that were developed by reverse…
New Insights into Lecanemab’s Role in Slowing Alzheimer’s Disease Progression A groundbreaking study led by Professor Kenjiro Ono of the Institute of Medical, Pharmaceutical, and Health Sciences at Kanazawa University, in collaboration with Eisai Co., Ltd., has uncovered a crucial…
CoolMonth Returns with Exciting Offers on CoolSculpting® Elite by Allergan Aesthetics Allergan Aesthetics, an AbbVie company has announced the return of its third annual CoolMonth celebration, showcasing CoolSculpting® Elite. This event offers a prime opportunity for individuals exploring non-surgical body…
Cytokinetics, Incorporated has announced the granting of equity awards as material inducements to new employees under Nasdaq Listing Rule 5635(c)(4). These grants, made on December 31, 2024, include stock options, restricted stock units (RSUs), and performance stock units (PSUs) offered…
The “Precision Medicine Software Market: Focused Insights 2024-2029” explores the dynamics Genomics of a rapidly growing industry. Valued at USD 1.72 billion in 2023, the market is expected to grow to USD 3.50 billion by 2029, reflecting a robust compound…
BeiGene a global oncology Chemotherapy company that plans to rebrand itself as BeOne Medicines Ltd., has achieved a significant milestone with the U.S. Food and Drug Administration’s (FDA) approval of TEVIMBRA® (tislelizumab-jsgr). This approval pertains to its use in combination…
Argenx SE a global immunology company dedicated to improving the lives of people affected by severe autoimmune diseases, has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVDURA for the treatment of adults with chronic inflammatory…
Bristol Myers Squibb has announced positive results from arthritis two pivotal Phase 3 trials, POETYK PsA-1 (IM011-054) and POETYK PsA-2 (IM011-055), which evaluated the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic arthritis (PsA). Both trials met…
In a significant victory for patient safety, the judge presiding over Eli Lilly’s case before the International Trade Commission (ITC) ruled that U.S. Customs and Border Protection should block the illegal importation of counterfeit tirzepatide products. This decision was grounded…
Regeneron Pharmaceuticals has announced positive Phase 2 results for two innovative monoclonal antibodies targeting distinct domains of Factor XI. REGN7508, designed to maximize anticoagulant activity while minimizing bleeding risk, targets the catalytic domain, while REGN9933, aimed at patients with the…
Roche has announced results from the Phase IIb PADOVA study investigating prasinezumab in 586 individuals with early-stage Parkinson’s disease. Participants received treatment for a minimum of 18 months while maintaining stable symptomatic therapies. The study’s primary endpoint, time to confirmed…
Viatris announced the publication of Phase 2b CARE study results evaluating the efficacy and safety of cenerimod in adults with moderate-to-severe systemic lupus erythematosus (SLE). The findings, published in Lancet Rheumatology, demonstrated that cenerimod 4 mg provided clinically meaningful and…
